Clinical trials
Idiopathic Pulmonary Fibrosis clinical trials
Below are recruiting idiopathic pulmonary fibrosis clinical trials, each written for real people, not researchers. We’re tracking 86 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06951217RecruitingPhase 2
Long-term safety study of an inhaled drug for lung scarring
This study continues treatment for people who already completed a previous study with an Avalyn inhaled antifibrotic drug. It aims to check the long-term safety of the medication for patients with certain types of lung scarring.
Birmingham, AlabamaAges 18 years+ - NCT07790614Recruiting
Comparing two CT scan methods for identifying pulmonary fibrosis
This study compares two types of CT scans to see which one is better at identifying idiopathic pulmonary fibrosis (IPF), a specific type of interstitial lung disease. You may be able to join if you have been diagnosed with ILD and are being discussed by a team of specialists.
Rozzano, ItalyAges 18 years+ - NCT07284602RecruitingPhase 3
Comparing a new drug to pirfenidone for lung scarring
This trial tests a new medicine, LYT-100 (deupirfenidone), against the standard drug pirfenidone for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the new drug works better or has fewer side effects.
Palm Spring, CaliforniaAges 40 years+ - NCT07284459RecruitingPhase 2
Testing PIPE 791 for idiopathic pulmonary fibrosis
This trial tests an investigational drug called PIPE 791 for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug slows lung function decline, and you may continue your current IPF medicine.
Mar del Plata, Buenos AiresAges 40 years+ - NCT07230288RecruitingPhase 2
Study of ABBV-142 for Idiopathic Pulmonary Fibrosis
This trial is testing a new antibody drug, ABBV-142, to see if it can reduce disease activity in adults with idiopathic pulmonary fibrosis (IPF). It may help if your IPF was diagnosed within the last 7 years and you meet certain health criteria.
Birmingham, AlabamaAges 40 years+ - NCT06968845RecruitingPhase 2
Study of LTI-03 for Idiopathic Pulmonary Fibrosis
This trial tests an inhaled drug called LTI-03 to see if it can help people with idiopathic pulmonary fibrosis (IPF). It may be an option for those with moderate lung function who are stable on their current treatment.
Birmingham, AlabamaAges 40 years+ - NCT01915511Recruiting
Long-term registry for new or worsening lung scarring
This study collects health information over time from people with newly diagnosed idiopathic pulmonary fibrosis (IPF) or other lung scarring diseases that are getting worse. It’s meant to better understand disease patterns and outcomes, which may help doctors plan future care.
Birmingham, AlabamaAges 21 years+ - NCT07743996Recruiting
Emotional and social experiences with fibrosis medications
This study looks at how people with pulmonary fibrosis feel emotionally and socially while taking antifibrotic medications like nintedanib or pirfenidone. It aims to understand the real-world impact of these treatments on daily life.
TokyoAges 40 years+ - NCT06967805RecruitingPhase 2
Study of MTX-463 for Idiopathic Pulmonary Fibrosis
This trial tests an experimental drug called MTX-463 for people with idiopathic pulmonary fibrosis (IPF). It aims to see if targeting a protein called WISP1 can slow lung scarring and help you breathe better.
Birmingham, AlabamaAges 40 years+ - NCT05674994RecruitingPhase 3
Steroid versus placebo for sudden worsening of lung scarring
This Phase 3 trial studies whether glucocorticoid (steroid) medicine helps people with idiopathic pulmonary fibrosis (IPF) who have a sudden flare-up, compared with an inactive placebo. You may be helped if steroids improve breathing and recovery during these acute episodes, but the study is designed to test that clearly.
AngersAges 18 years+ - NCT07036523RecruitingPhase 2
Study of BI 765423 for people with Idiopathic Pulmonary Fibrosis (IPF)
This trial tests a new medicine, BI 765423, to see if it can improve lung function in people with IPF, a lung scarring disease. You can join whether or not you are already taking standard treatments like nintedanib or pirfenidone.
Birmingham, AlabamaAges 40 years+ - NCT04905693Enrolling by invitationPhase 3
Extension inhaled treprostinil study for fibrotic lung disease
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
Birmingham, AlabamaAges 40 years+ - NCT07723872Recruiting
Finger vs. earlobe oxygen test during a 6-minute walk
This study compares oxygen levels measured at the finger versus the earlobe during a 6-minute walk test for people with interstitial lung disease. It helps find the most accurate way to monitor your oxygen during exercise.
Granollers, SpainAges 18 years+ - NCT07679893RecruitingPhase 2
Inhaled nintedanib for idiopathic pulmonary fibrosis
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
Windsor, OntarioAges 40–80 - NCT07516951RecruitingPhase 2
Study of zampilimab for idiopathic pulmonary fibrosis
This trial tests an investigational drug called zampilimab for people with idiopathic pulmonary fibrosis (IPF). It aims to find a safe and effective dose that may slow lung function decline.
SkopjeAges 40 years+ - NCT07707245Recruiting
Finding biomarkers in lung disease and lung cancer
This trial studies blood and tissue samples from people with COPD, IPF, or lung cancer to find markers that can help diagnose and predict these conditions. It aims to discover why some lung diseases progress to cancer.
Milan, MilanAges 18 years+ - NCT03120481Recruiting
Check how respiratory health changes in people without lung problems
This trial enrolls adults who recently had a chest X-ray as part of routine health screening and did not show major abnormal findings, and who do not have significant breathing symptoms. It may help researchers understand changes in respiratory health over time and improve how respiratory disease risk is monitored.
Seoul, SeoulAges 19–90 - NCT03437486Recruiting
Family study for inherited lung scarring causes
This study looks at what causes familial (inherited) pulmonary fibrosis by studying relatives who are not yet diagnosed with the lung disease. You may help researchers understand risk and early changes in the lungs within families.
Nashville, TennesseeAges 40–75 - NCT03478553Recruiting
Study of genes in people with pulmonary fibrosis
This study looks at genetic (inherited) factors related to pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF). It may help researchers understand why some families are more affected and could guide future testing or treatments.
Aurora, ColoradoAges 18 years+ - NCT03535545RecruitingPhase 1
PET-MRI imaging test in lung cancer and lung disease
This Phase 1 study tests a radioactive imaging agent to help doctors see disease activity in the lungs using PET/MRI scans. It includes healthy volunteers and people with lung cancer, idiopathic pulmonary fibrosis, lung transplant–related lung problems, or certain medication-related lung inflammation.
Boston, MassachusettsAges 18–80 - NCT04160715Recruiting
Registry for people with idiopathic pulmonary fibrosis in Korea
This study is a registry that collects health information from people diagnosed with idiopathic pulmonary fibrosis (IPF). It may help researchers better understand IPF and how it changes over time, even if it doesn’t involve a new medication.
Seongnam-siAges 30–100 - NCT04362644RecruitingPhase 1
Imaging agent study for idiopathic pulmonary fibrosis lung scarring
This Phase 1 study tests a specialized imaging agent that can help show differences (heterogeneity) in lung scarring in idiopathic pulmonary fibrosis (IPF). It’s mainly about safety and whether the imaging works for people with certain genetic and lung-function features.
Birmingham, AlabamaAges 40–85 - NCT04965298RecruitingPhase 3
Lansoprazole add-on treatment for idiopathic pulmonary fibrosis
This Phase 3 study tests whether adding lansoprazole (a stomach acid medicine) can improve outcomes for people with idiopathic pulmonary fibrosis (IPF). You may already be on IPF “anti-fibrotic” medication, and the study checks if the added lansoprazole helps, compared with placebo.
Norwich, NorfolkAges 40 years+ - NCT05098717Recruiting
PEEP settings guided by lung pressure in pulmonary fibrosis
This trial tests whether using lung-pressure measurements to adjust ventilator PEEP (a breathing-support setting that keeps airways open) can help people with pulmonary fibrosis who are on a breathing machine for acute respiratory failure. It may improve breathing comfort and oxygenation by finding the best PEEP level for you.
ModenaAges 18–90
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Idiopathic Pulmonary Fibrosis trials by city
Studies with a site in or near these metro areas.
Idiopathic Pulmonary Fibrosis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for idiopathic pulmonary fibrosis?
- Yes. Clin2 currently lists 86 recruiting idiopathic pulmonary fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a idiopathic pulmonary fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a idiopathic pulmonary fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.